carbamazepine has been researched along with Allergic Encephalomyelitis in 2 studies
Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.
carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Carbamazepine and oxcarbazepine were not immunosuppressive in lymphocyte-driven autoimmunity, but slowed the accumulation of disability in experimental autoimmune encephalomyelitis when administered during periods of the inflammatory penumbra after active lesion formation, and was shown to limit the development of neurodegeneration during optic neuritis in myelin-specific T cell receptor transgenic mice." | 3.80 | Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis. ( Al-Izki, S; Amor, S; Baker, D; Browne, L; Clutterbuck, L; Edith Chan, AW; Garthwaite, J; Gerritsen, WH; Giovannoni, G; Hankey, DJ; Joel, SP; Lidster, K; Montoya, A; Peferoen-Baert, R; Perkins, V; Posada, C; Pryce, G; Selwood, DL; Ummenthum, K; van der Valk, P; von Kutzleben, SM, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Izki, S | 1 |
| Pryce, G | 1 |
| Hankey, DJ | 1 |
| Lidster, K | 1 |
| von Kutzleben, SM | 1 |
| Browne, L | 1 |
| Clutterbuck, L | 1 |
| Posada, C | 1 |
| Edith Chan, AW | 1 |
| Amor, S | 1 |
| Perkins, V | 1 |
| Gerritsen, WH | 1 |
| Ummenthum, K | 1 |
| Peferoen-Baert, R | 1 |
| van der Valk, P | 1 |
| Montoya, A | 1 |
| Joel, SP | 1 |
| Garthwaite, J | 1 |
| Giovannoni, G | 1 |
| Selwood, DL | 1 |
| Baker, D | 1 |
| Black, JA | 1 |
| Liu, S | 1 |
| Carrithers, M | 1 |
| Carrithers, LM | 1 |
| Waxman, SG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| OxCarbazepine as a Neuroprotective Agent in MS: A Phase 2a Trial[NCT02104661] | Phase 2 | 30 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for carbamazepine and Allergic Encephalomyelitis
| Article | Year |
|---|---|
Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Biological Specimen Ba | 2014 |
Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine.
Topics: Animals; Anticonvulsants; Antigens, CD; Axons; Carbamazepine; Cell Count; Disease Models, Animal; En | 2007 |